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Background: Dysregulated protein kinase signaling is involved in the pathogenesis of many chronic diseases.
However, the dysregulated signaling pathways critical to prion pathogenesis remain incompletely characterized.
Global analyses of signaling pathways may be useful to better characterize these pathways. We therefore set out to
develop such global assays. To this end, we used as a model cytoplasmic mutants of the cellular prion protein
(PrPC), which are toxic to N2a neuroblastoma cells. We tested the global assays for their sensitivity to detect
changes in signaling pathways in cells expressing cytoplasmic PrP mutants.
Methods: We developed a targeted proteomics (kinomics) approach using multiplex Western blots to identify
signaling pathways dysregulated in chronic neurological pathologies. We tested the approach for its potential
ability to detect signaling changes in N2a cells expressing cytoplasmic PrP mutants.
Results: Multiplex Western blots were designed to quantitate the expression levels of 137 protein kinases in a
single membrane and using only 1.2 mg of sample. The response of the blots was sensitive and linear to changes
of 6% in protein levels. Hierarchical and functional clustering of the relative expression levels identified an mTOR
signaling pathway as potentially dysregulated in N2a cells expressing cytoplasmic PrP. The mTOR signaling pathway
regulates global protein synthesis, which is inhibited in cells expressing cytoplasmic PrP. The levels of proteins
involved in the Akt1/p70S6K branch of mTOR signaling changed in synchrony with time of cytoplasmic PrP
expression. Three kinases in this pathway, Akt, p70S6K, and eIF4B were in their inactive states, as evaluated by
phosphorylation of their regulatory sites.
Conclusion: The results presented are consistent with the previously reported inhibition of Akt/p70S6K/eIF4B
signaling as mediating pathogenesis of cytoplasmic PrP. We conclude that the kinomic analyses are sensitive and
specific to detect signaling pathways dysregulated in a simple in vitro model of PrP pathogenesis.
Keywords: Prion disease, Cytoplasmic PrP, Neurotoxicity, Kinomics, Protein kinase, Multiplex Western blots, Akt,
p70S6K, eIF4BBackground
Dysregulation of protein kinase signaling is implicated in
the pathogenesis of many chronic diseases, including neu-
rodegenerative diseases such as Alzheimer’s and Parkinson’s
[1-3]. Not surprisingly, inhibitors of protein kinases are the
largest group of new cancer therapeutics [4]. Thirty-one* Correspondence: luis.schang@ualberta.ca
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approximately 2,700 clinical trials, and thousands more
are in various stages of pre-clinical development ([4-6]
and summary of [7]). Up to 30% of the research and devel-
opment budget of the pharmaceutical industry is esti-
mated to be invested towards protein kinase inhibitors
[8,9]. Considering the importance of protein kinases in
chronic disease, it would be desirable to have approaches
to identify protein kinase signaling pathways that are dys-
regulated in chronic diseases.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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prion diseases, are a family of chronic neurodegenerative
diseases against which there are no preventative or thera-
peutic treatments [10]. Prion diseases are invariably lethal to
humans (kuru; Creutzfeldt-Jakob disease, CJD; Gerstmann-
Sträussler-Scheinker disease, GSS; fatal familial insomnia,
FFI), and other species such as cattle (bovine spongiform
encephalopathy, BSE), goat, sheep (scrapie), deer, elk
and moose (chronic wasting disease, CWD) [11,12]. The
characteristic neuropathology of prion diseases includes
gliosis, spongiform degeneration, and neuronal death. The
conversion of the cellular prion protein (PrPC) to an abnor-
mal conformation (PrPSc) is widely accepted to be essential
for pathogenesis. However, the molecular mechanisms
whereby such conversion eventually mediates the conse-
quent neurodegeneration are not yet fully understood.
Considering the critical roles that protein kinases play in
the pathogenesis of other chronic neurodegenerative dis-
eases, it is not surprising that they also participate in that
of prion diseases. For example, feline Gardner-Rasheed
sarcoma virus oncogene cellular homolog/Yamaguchi 73
and Esh avian sarcoma virus oncogene cellular homolog-
related novel protein kinase (Fyn) knockout mice died
faster than wild-type mice after scrapie infection [13].
Conversely, inhibition of protein kinase R-like endoplasmic
reticulum kinase (PERK) by the overexpression of growth
arrest and DNA damage-inducible protein 34 (GADD34)
prolonged survival of scrapie-infected mice [14]. The acti-
vation of vascular endothelial growth factor receptor
(VEGFR) inhibited death of cultured neurons treated
with the neurotoxic prion peptide PrP106-126 [15].
The Abelson leukemia oncogene cellular homolog (c-Abl)/
Hardy-Zuckerman 4 feline sarcoma virus oncogene cellular
homolog (c-Kit)/platelet-derived growth factor receptor
(PDGFR) inhibitor STI571 impaired scrapie neuroinvasion
and prolonged survival of mice after intraperitoneal infec-
tion [16]. Several other inhibitors of protein kinases regu-
lated PrPSc accumulation in scrapie-infected cultured
cells [17-22]. Unfortunately, the signaling pathways most
critical to prion disease pathogenesis have yet to be fully
identified.
Although prion diseases are characterized by the accu-
mulation of PrPSc, endogenous PrPC is also required for
pathogenesis [23-26]. PrPC is physiologically attached to
the outside of the plasma membrane via a glycosylpho-
sphatinositol (GPI) anchor [27,28]. PrPC may accumulate
in the cytoplasm as a result of inefficient endoplasmic
reticulum (ER)-targeting [29-31], ER-associated degrad-
ation [32-34], alternative translation initiation [35], or
persistent pre-emptive quality control [36]. Low levels of
cytoplasmic PrP have been observed in certain subpopu-
lations of neurons without overt neurodegeneration
[37-39], and the roles of cytoplasmic PrP in prion infec-
tion are disputed [40]. Nonetheless, the accumulation ofPrPC in the cytoplasm is often neurotoxic and has also
been considered as a possible neurodegeneration mech-
anism [41]. Mice expressing a truncated mutant of
PrPC lacking its N-terminal ER-targeting and C-terminal
GPI-membrane-anchoring signals (named cytoplasmic
PrP, or CyPrP) suffered from ataxia with gliosis and cere-
bellar degeneration [42]. The molecular mechanisms
of such neurodegeneration can be studied in culture
because CyPrP is also toxic to mouse N2a neuroblast-
oma cells [42].
The expression of CyPrP inhibits heat shock protein 70
(Hsp70) synthesis in stressed N2a cells [43]. Hsp70 over-
expression inhibits CyPrP-mediated toxicity, suggesting
that the inhibition of Hsp70 synthesis may contribute to
cell death [44,45]. Hsp70 promotes assembly and activa-
tion of the mammalian target of rapamycin complex 2
(mTORC2; consisting of mammalian target of rapamycin
[mTOR], rapamycin-insensitive companion of mTOR [ric-
tor], mammalian lethal with SEC13 protein 8 [mLST8]
and stress-activated protein kinase-interacting protein 1
[SIN1]), which then activates AKT8 virus oncogene cellu-
lar homolog (Akt)/ribosomal protein S6 kinase, 70 kilodal-
ton, polypeptide 1 (p70S6K)/eukaryotic initiation factor
4B (eIF4B) signaling [46,47]. Active eIF4B promotes pro-
tein synthesis, which is otherwise inhibited in cells ex-
pressing CyPrP [43,48].
Here, we describe the development of a multiplex Western
blot-based kinomics approach. Before embarking on the
analysis of prion infected animals, we used a simple
in vitro model to test the sensitivity of the approach to
identify dysregulated signaling pathways, accumulation of
enhanced green fluorescent protein-tagged cytoplasmic
PrP (CyPrPEGFP) in N2a cells. The approach identified the
Hsp70-regulated Akt/p70S6K/eIF4B signaling pathway
to be inhibited in cells expressing CyPrPEGFP, consistently
with previously known consequences of CyPrPEGFP ex-
pression [43]. The results support the ability of the
kinomics approach to detect signaling pathways dysregu-
lated in an in vitro model of prion pathogenesis. As de-
scribed in the companion manuscript, we have applied
this approach to an in vivo model, infection of mice with
mouse-adapted scrapie, to discover two signaling path-
ways dysregulated during prion disease pathogenesis.
Results
Multiplex Western blots quantitate the expression levels
of 137 protein kinases or regulatory subunits in only
1.2 mg of sample
We developed multiplex Western blots to analyze the
expression levels of protein kinases potentially involved
in prion pathogenesis. In these assays, protein extracts
are run in SDS-PAGE in a single well, transferred to a
membrane and probed with several pools of antibodies
in a multiplex Western blot apparatus.
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the use of mice to identify and analyze protein kinases
of potential importance in human disease. We per-
formed an extensive literature search for human protein
kinases that may be involved in prion or other neurodegen-
erative diseases (Alzheimer’s, Parkinson’s, Huntington’s,
multiple sclerosis, or amyotrophic lateral sclerosis). We
also included protein kinases involved in cellular patholo-
gies associated with prion disease (neuronal apoptosis,
gliosis, glial activation, neuronal degeneration, or neuronal
survival). The search was restricted to protein kinases the
mouse orthologs of which were detected by antibodies
commercially available at the time. Following these cri-
teria, we selected 145 protein kinases, almost 30% of the
540 or 518 protein kinases in the mouse or human
kinomes, respectively (Additional file 1: Figure S1) [49,50].
The selected protein kinases are distributed among the
eight groups of protein kinases (AGC, CAMK, CMGC,
CK1, STE, TK, TKL, and atypical) [50]. The most under-
represented kinases in the selection are involved in muscle
contraction [myosin light chain kinases, MLCK], sperm-
atogenesis [testis specific serine/threonine kinases, TSSK],
or developmental processes [transforming growth factor-
beta receptor kinases, TGF-β]), which are not expected to
be critical in prion disease. We also included the eleven
cyclins or cyclin-like proteins (p25/p35, p39), which are
the activating subunits required for the activity of the
catalytic cyclin-dependent kinase (CDK) moiety of the ac-
tive CDK/cyclin heterodimers.
Our long-term objective was to analyze the kinomic
changes in brains of scrapie-infected mice (see compan-
ion paper). We therefore optimized the antibodies in
multiplex Western blots with mouse brain homogenate.
Antibodies specific for 122 protein kinases or regulatory
subunits (Additional file 2: Table S1) recognized their
cognate proteins in 1.2 mg of mouse brain homogenate
(200 μg loaded per linear cm). We selected the dilution
of each antibody that resulted in maximum signal intensity
and minimum background with no antibody saturation
(i.e., signal did not increase with increasing antibody con-
centrations). Antibodies specific for calcium/calmodulin-
dependent kinase 4 (CaMK4), mitogen-activated protein
kinase/extracellular signal-regulated kinase 5 (MEK5), and
Jun N-terminal kinase 2 (JNK2) detected two isoforms
each. Fifteen antibodies specific for proteins not recognized
in mouse brain homogenate were optimized in Western
blots using lysate from cultured 3T3 mouse fibroblasts
(200 μg loaded per linear cm). The remaining 19 anti-
bodies did not detect their cognate protein in mouse brain
homogenate or 3T3 cell lysates.
The multiplex Western blots were tested for reprodu-
cibility. Mouse brain homogenate resolved throughout a
single-well gel (1.2 mg; 200 μg per linear cm) was trans-
ferred, and 16 lanes were isolated in the membrane with amulti-screen apparatus. The extracellular signal-regulated
kinases (Erk) 1 and 2 were probed in each of the 16 lanes.
The standard deviation between all 16 lanes was only 2.2%
or 1.0% of the average for Erk1 or Erk2, respectively, and
the range was 8% of the average for Erk1 or 4% of Erk2.
To minimize the variability and amount of sample re-
quired, multiple proteins were probed for in each lane of
a single membrane. The 137 proteins were grouped into
32 sets such that each set contained proteins of molecu-
lar weights clearly resolved in SDS-PAGE, detected by
antibodies of different species and recognized by the
antibodies giving the weakest or strongest signals (Sets 1
and 2, respectively). The membranes were probed first for
the 16 sets containing the proteins that resulted in the
lowest signal intensities (Figure 1), stripped (only once)
and reprobed for the remaining 16 sets. All 122 protein ki-
nases or regulatory subunits previously detected in standard
Western blots were detected in the multiplex blots. The
following protein kinases were detected in Set 1. Lane 1:
DAPK1 (not visible, 145 kDa), non-specific (green, 95 kDa),
Syk (not visible, 74 kDa), CaMK4β (not visible, 66 kDa),
CaMK4 (red, 63 kDa), CK1γ1 (green, 45 kDa), non-specific
(green, 42 kDa), cyclin D3 (red, 33 kDa), non-specific
(green, 32, 25 kDa). DAPK1, Syk, and CaMK4β are not
visible at the exposure shown. Lane 2: HER2 (not vis-
ible, 160 kDa), RSK1 (green, 85 kDa), AMPKα1 (not
visible, 64 kDa), CK1γ2 (not visible, 55 kDa), non-specific
(green, 45 kDa; red, 43, 40, 35 kDa; green, 25 kDa). HER2,
AMPKα1, and CK1γ2 are not visible at the exposure
shown. Lane 3: ROCK1 (not visible, 162 kDa), GRK2
(green, 80 kDa), p70S6K (red, 75 kDa), PCTAIRE3 (green,
48 kDa), non-specific (green, 40 kDa), cyclin H (not vis-
ible, 37 kDa), non-specific (green, 27 kDa). ROCK1 and
cyclin H are not visible at the exposure shown. Lane 4:
JAK1 (red, 125 kDa), MARK4 (not visible, 80 kDa), PLK1
(red, 66 kDa), non-specific (green, 65 kDa; red, 52 kDa),
MAPKAPK2 (not visible, 48 kDa), non-specific (red, 48,
45, 42, 40 kDa), p25/p35 (green, 35 kDa). MARK4 and
MAPKAPK2 are not visible at the exposure shown.
Lane 5: HER3 (red, 185 kDa), Raf1 (red, 71 kDa), Fms/
CSF1R (not visible, 50 kDa), cyclin D1 (red, 36 kDa).
Fms/CSF1R is not visible at the exposure shown. Lane 6:
CRIK (not visible, 220 kDa), MSK1 (not visible, 90 kDa),
non-specific band (green, 65, 45, 38 kDa). CRIK and MSK1
are not visible at the exposure shown. Lane 7: Non-
specific (green, 170 kDa), MLK3 (not visible, 90 kDa),
PDK1 (green, 60 kDa), CK1α (not visible, 42 kDa), CK2α1
(not visible, 40 kDa). MLK3, CK1α, and CK2α1 are not
visible at the exposure shown. Lane 8: Non-specific (green,
80 kDa), GRK5 (green, 65 kDa), non-specific (green, 52
kDa), p38α (not visible, 42 kDa), non-specific (green, 40
kDa). p38α is not visible at the exposure shown. Lane 9:
Non-specific (red, 250 kDa), PKD2 (not visible, 98 kDa),
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Figure 1 Multiplex Western blots detect 122 selected protein kinases in only 1.2 mg of mouse brain. A single-well gel was loaded with
1.2 mg of mouse brain homogenate, and the proteins were resolved and transferred. A multi-screen apparatus isolated 16 individual lanes within
the area of homogeneously resolved protein and probed with optimized antibodies specific for 122 selected protein kinases. Molecular weights
in kDa are indicated on the left. Signal from secondary antibody labeled with Alexa Fluor 680 (red bands) and IRDye 800 (green bands) was detected
using a LI-COR Odyssey infrared imaging system. Yellow bands, red-labeled goat anti-mouse secondary antibody detected by green-labeled anti-goat
secondary antibody. Due to the wide range in expression levels, no single exposure of the blot can show all the bands. The bands that are visible in
each lane at the exposure shown are listed (from top to bottom) in the main text.
Shott et al. Virology Journal 2014, 11:175 Page 4 of 18
http://www.virologyj.com/content/11/1/175(green, 51 kDa), CDK7 (not visible, 41 kDa). PKD2 and
CDK7 are not visible at the exposure shown. Lane 10:
TrkB (red, 130 kDa), Erk5 (green, 110 kDa), MST1 (not vis-
ible, 60 kDa), CK1ε (red, 44 kDa), non-specific (green, 34
kDa). MST1 is not visible at the exposure shown. Lane 11:
PKD1 (green, 112 kDa), IKKβ (not visible, 88 kDa), Akt3
(green, 60 kDa), MKK7 (not visible, 46 kDa), p38β (green,
42 kDa). IKKβ and MKK7 are not visible at the exposure
shown. Lane 12: EphA1 (not visible, 180 kDa), InsR (not
visible, 130 and 88 kDa), non-specific (green, 80 kDa), RIPK2
(not visible, 60 kDa), non-specific (green, 45, 35 kDa).
EphA1, InsR, and RIPK2 are not visible at the exposure
shown. Lane 13: ATM (not visible, ~300 kDa), PRK2
(not visible, 130 kDa) B-Raf (red, 90 kDa), non-
specific (red, 65 kDa), Myt1 (green, 63 kDa), non-
specific (red, 42, 35 kDa). ATM and PRK2 are not
visible at the exposure shown. Lane 14: c-Abl (not visible,
130 kDa), PAK3 (green, 65 kDa), CaMK1α (green, 42
kDa). c-Abl is not visible at the exposure shown. Lane 15:
PKD3 (not visible, 95 kDa), cyclin A (not visible, 60 kDa),
both are not visible at the exposure shown. Lane 16:
Non-specific (red, 120 kDa), Akt2 (green, 60 kDa), Lck
(not visible, 56 kDa). Lck is not visible at the exposure
shown. The following protein kinases were detected in
Set 2. Lane 1: ROCK2 (red, 183 kDa), Akt1 (red, 60 kDa),
SGK3 (green, 50 kDa), non-specific (green, 45 kDa), Erk2
(red, 42 kDa), non-specific (green, 36 kDa). Lane 2:
TNIK (red, 180 kDa), PKCε (red, 90 kDa), MEK2 (red,
45 kDa). Lane 3: EphA7 (not visible, 86 kDa), PKCδ (not
visible, 78 kDa), GSK3α (not visible, 50 kDa), all are not
visible at the exposure shown. Lane 4: Non-specific
(green, 140 kDa), DYRK1A (green, 90 kDa), IKKα (not
visible, 80 kDa), non-specific (green, 80 kDa), PKR (not
visible, 66 kDa), non-specific (green, 63 kDa), PKACβ(green, 53 kDa), non-specific (green, 42 kDa). IKKα and
PKR are not visible at the exposure shown. Lane 5: TrkC
(not visible, 145 kDa), CaMK2γ (not visible, 60 kDa), cyc-
lin E1 (not visible, 55 kDa), PKACα (red, 42 kDa). TrkC,
CaMK2γ, and cyclin E1 are not visible at the exposure
shown. Lane 6: DDR1 (green, 109 kDa), PKCζ (red, 86
kDa), non-specific (green, 80 kDa), JNK2α2/β2 (red-partly
covered by adjacent non-specific band, 52 kDa), non-
specific (green, 44 kDa), JNK2α1/β1 (red, 42 kDa), MKK6
(green, 38 kDa), cyclin G1 (not visible, 29 kDa). cyclin G1
is not visible at the exposure shown, and JNK2α1/β1 due
to signal from adjacent non-specific band. Lane 7: TrkA
(not visible, 138 kDa), PKCι (not visible, 75 kDa), MEK5α
(red, 55 kDa), MEK5β (red, 45 kDa). TrkA and PKCι are
not visible at the exposure shown. Lane 8: PKCγ (red, 80
kDa), CaMK1δ (not visible, 44 kDa), non-specific (red, 45,
43 kDa). CaMK1δ is not visible at the exposure shown.
Lane 9: EphA3 (green, 140 kDa), non-specific (green, 120
kDa), CASK (red, 104 kDa), GSK3β (red, 46 kDa), p38γ
(green, 43 kDa), CDK5 (red, 30 kDa). Lane 10: ASK1 (not
visible, 155 kDa) and p39 (not visible, 40 kDa), both are
not visible at the exposure shown. Lane 11: MEKK1 (not
visible, 205 kDa), PINK1 (not visible, 66 kDa), Fyn (not
visible, 59 kDa), and p38δ (not visible, 43 kDa), all are not
visible at the exposure shown. Lane 12: EphA4 (red, 120
kDa), PAK1 (green, 68 kDa), Lkb1 (not visible, 55 kDa),
PKACγ (green, 40 kDa). Lkb1 is not visible at the expos-
ure shown. Lane 13: HER4 (not visible, 182 kDa), JAK2
(not visible, 122 kDa), PKG1 (not visible, 76 kDa), Src (not
visible, 60 kDa), Nek6 (green, 45 kDa). HER4, JAK2, PKG1,
and Src are not visible at the exposure shown. Lane 14:
SLK (red, 220 kDa), HGK (green, 140 kDa), PKCα (red,
82 kDa), LIMK1 (green, 70 kDa), Erk1 (green, 44 kDa),
non-specific (green, 40, 38 kDa). Lane 15: PRK1 (red,
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CDKL1 (not visible, 42 kDa). CDKL1 is not visible at the
exposure shown. Lane 16: Pyk2 (red, 115 kDa), CaMKK2
(not visible, 66 kDa), JNK1 (green, 50 kDa), non-specific
(green, 45 kDa). CaMKK2 is not visible at the exposure
shown.
Importantly, the multiplex Western blots allowed for
the identification and resolution of: (i) kinases yielding
high and low intensity signal (for example, Set 1; Akt3 in
lane 11 [green band at 60 kDa] vs. Akt2 in lane 16
[green band at 60 kDa]); (ii) kinases of similar molecular
weight in the same lanes (for example, Set 1, lane 3;
GRK2 [green band at 80 kDa] and p70S6K [red band at
75 kDa]); and (iii) as many as 5 protein kinases in a sin-
gle lane (for example, Set 2 lane 9: EphA3 [green band
at 140 kDa], CASK [red band at 104 kDa], GSK3β [red
band at 46 kDa], p38γ [green band at 43 kDa], CDK5
[red band at 30 kDa]; Set 2, lane 14; SLK [red band at
220 kDa], HGK [green band at 140 kDa], PKCα [red
band at 82 kDa], LIMK1 [green band at 70 kDa], Erk1
[green band at 44 kDa]) (Figure 1).
In summary, we developed multiplex Western blots to
quantitate 137 protein kinases or regulatory subunits in-
volved in neurological diseases or pathologies using only
1.2 mg of sample on a single membrane stripped only once.
Multiplex Western blots are sensitive and linear,
detecting incremental 6 (or 3)% changes in protein levels
We next tested the variability and linearity of the multi-
plex Western blots to increases in protein levels. Fifteen
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Figure 2 Multiplex Western blots are sensitive and linear, detecting in
presenting the relative signal intensity of the indicated protein kinases exp
of 3T3 lysate, or the protein kinases expressed in brain but not in 3T3 cells
Mouse brain homogenate was spiked with incremental 3, 6, 9, or 12%, or 6
and probed by multiplex Western blot. The Western blots for CDK1, RSK2, CH
incremental changes, are shown at the bottom of each graph as examples. Tdetected in mouse brain homogenate but were detected in
cell lysate from 3T3 mouse fibroblasts. Mouse brain hom-
ogenate was spiked with incremental 6% (average of the
range of the reproducibility of quantitations, as evaluated
for Erk1 and Erk2) increases of 3T3 cell lysate, from 0 to
24%. Six of the proteins detected only in 3T3 cell lysates
(CDK1, CDK4, PDGFRβ, ribosomal protein S6 kinase 2
[RSK2], checkpoint kinase 1 [CHK1], Bruton’s tyrosine
kinase [BTK]) were quantitated. Their levels increased
linearly (r2 ≥ 0.94, P < 0.001) along the increases in 3T3
cell lysate from 0 to 24% (Figure 2A), and those of protein
kinase C theta (PKCθ) with incremental 3% increases of
the 3T3 cell lysate from 0 to 12% (r2 = 0.96, P < 0.0001).
To test the sensitivity to decreases in protein levels, we
analyzed the levels of four protein kinases (PKCγ, CaMK4,
p39, and tropomyosin-related kinase B [TrkB]) detected in
mouse brain but which are not expressed in 3T3 cells
[51-55]. Their levels decreased linearly (r2 ≥ 0.87, P < 0.01)
along the incremental 6% (PKCγ, CaMK4) or 3% (TrkB,
p39) decreases of mouse brain homogenate from 100 to
76% (Figure 2B). The multiplex Western blots are repro-
ducible, sensitive and linear, detecting incremental 6% in-
creases or decreases in protein levels.
Primary kinomic screens of N2a cells expressing
cytoplasmic PrP mutants identified the mTOR signaling
pathway as potentially dysregulated
To identify potentially dysregulated signaling pathways,
protein kinases with similar changes in relative expression
levels were blindly clustered by agglomerative unsupervised
hierarchical clustering (Figure 3). Any clusters containingB
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Figure 3 Flow chart of the kinomic analyses. Algorithm used to
identify dysregulated signaling pathways.
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were next identified by literature and signal transduction
database searches. The different treatments used in the
clustering must affect the same signaling pathways differ-
ently, or affect different signaling pathways altogether, for
this approach to detect relevant clusters.
The neurotoxicity of CyPrP expression requires resi-
dues 116–156 [44]. We transfected N2a neuroblastoma
cells with CyPrP or two mutants truncated within this re-
gion, CyPrP124stop and CyPrP124-230. The expression of
CyPrP124stop is not toxic to N2a cells [56], and cells ex-
pressing CyPrP124-230 also are healthy, although toxicity
has not been quantitatively assessed. We expected cells
expressing CyPrP to affect different subsets of signalingpathways than, or to differentially affect the same signaling
pathways as, those expressing CyPrP124stop or CyPrP124-
230. Such differentially affected signaling pathways might
be involved in CyPrP-mediated neurotoxicity.
The cytoplasmic PrP mutants were tagged with en-
hanced green fluorescent protein (EGFP) to evaluate
transfection efficiencies (Additional file 3: Figure S2), as
described previously [56]. Lysates collected from N2a cells
24 h after transfection with empty vector, used as control,
or vector encoding for CyPrPEGFP, CyPrPEGFP124stop, or
CyPrPEGFP124-230 were subjected to multiplex Western
blot (Figure 4, Additional file 4: Figure S3). The densito-
metric data from the 76 protein kinases detected in cells
expressing all mutants were normalized to the levels in
the cells transfected with the empty vector and then ana-
lyzed by unsupervised hierarchical clustering.
We first performed hierarchical clustering of the three
PrP mutants to evaluate any potential (unexpected) similar-
ities in changes in protein kinase expression. If two different
cytoplasmic PrP mutants resulted in identical changes in
protein kinase expression, the correlation would be 1; a cor-
relation of 0 indicates no relationship. The city-block dis-
tance metric correlation between CyPrPEGFP124stop and
CyPrPEGFP124-230 was 0.088, and between them and
CyPrPEGFP was 0. The lack of the correlation indicated that,
as expected, the different cytoplasmic PrP mutants dysregu-
lated different signaling pathways.
We next performed hierarchical clustering of protein ki-
nases by their expression levels in cells transfected with
each of the three cytoplasmic PrP mutants (Figure 5). The
log2 relative expression levels were classified in categories
each encompassing 18% changes in expression, three times
the 6% changes that the tests detect linearly (Figure 2). We
then identified the clusters that contained protein ki-
nases involved in any given signaling pathways. We
were most interested in clusters containing protein ki-
nases that were expressed to different levels in cells
expressing CyPrPEGFP than in cells expressing
CyPrPEGFP124stop or CyPrPEGFP124-230. We excluded
clusters containing protein kinases expressed to similar
levels in cells expressing empty vector or CyPrPEGFP. Five
clusters were identified following these criteria (Figure 5,
grey boxes). The mTOR signaling pathway includes the
mTOR complex 2 (mTORC2), which activates Akt,
PKCα, and SGK1, and the mTOR complex 1 (mTORC1),
which activates p70S6K and eukaryotic initiation factor
4E-binding protein (eIF4E-BP) [57]. Two clusters contain-
ing protein kinases most affected in cells expressing
CyPrPEGFP included all the mTORC substrates included in
the primary screens (PKCα, Akt, p70S6K) (Figure 5, i
and ii). PKCα and p70S6K clustered together because
their levels were lowest in cells expressing CyPrPEGFP. Ad-
enosine monophosphate-activated protein kinase catalytic





































Figure 4 Differential expression of protein kinases in N2a cells expressing different cytoplasmic PrP mutants. Multiplex Western blots of
lysates from N2a cells transfected with empty vector (vector), or vector encoding CyPrPEGFP (CyPrP), CyPrPEGFP124stop (124stop), or CyPrPEGFP124-230
(124–230). Molecular weights in kDa are indicated on the right. The protein kinases p70S6K (set 1) and PKACβ (set 2) are indicated by
white arrowheads and enlarged, to illustrate their differential expression in cells expressing the different mutants.
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http://www.virologyj.com/content/11/1/175signaling, clustered together with Akt1 because their levels
were highest in cells expressing CyPrPEGFP. The mTOR
signaling pathway regulates protein synthesis, which is
inhibited in cells expressing CyPrPEGFP [43]. The results
from the primary kinomic screens therefore suggested that
CyPrP-mediated neurotoxicity in N2a cells might involve
dysregulated mTOR signaling.
The levels of proteins in the Akt1/p70S6K branch of the
mTOR signaling pathway decreased synchronously with
time of CyPrPEGFP expression
If the changes in the levels of the proteins involved in
mTOR signaling were the result of CyPrPEGFP expression,
then their levels would be expected to change in synchronywith time of expression. We analyzed three sets of N2a
cell lysates prepared 12, 24 and 48 h after transfection
with the CyPrPEGFP-expressing construct in three inde-
pendent biological repeats. Cells expressing EGFP were
used as control.
The levels of EGFP increased from 12 to 48 h after
transfection (Figure 6). In contrast, those of CyPrPEGFP
changed little (slightly decreased) with time. Targeted
secondary analyses characterized the expression levels of
ten proteins involved in the mTOR signaling pathway.
Four of the antibodies used in these targeted multiplex
Western blots had already been used in the primary
screen (Akt1, p70S6K, PKCα, AMPKα1). New antibodies
were selected to analyze two protein kinases (mTOR and
Figure 5 Identification of the mTOR signaling pathway as
potentially dysregulated in cells expressing CyPrPEGFP.
Hierarchical clustering of 76 protein kinases using the normalized
and log2 transformed densitometric data from primary multiplex
Western blots. Red, higher expression levels; green, lower expression
levels. Each category encompasses changes in expression levels of
18% (0.23 in log2 scale), 3 times the 6% linear changes detected by
the technique. Grey boxes indicate clusters of protein kinases most
differentially expressed in cells expressing CyPrPEGFP. The clusters (i)
and (ii) consist of PKCα, p70S6K, Akt1, and AMPKα1 involved in
mTOR signaling. The protein kinases highlighted in Figure 4, p70S6K
and PKACβ, are indicated by (●).
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[Mnk1]) and four downstream substrates (eIF4B, eukaryotic
initiation factor 4E [eIF4E], ribosomal protein S6 [S6], and
eukaryotic elongation factor 2 [eEF2]), which were not
included in the primary screens. These antibodies were
optimized as those used in the primary screens. The nor-
malized expression levels were grouped into categories
spanning 20% changes, slightly above 3 times the 6%
changes that the tests detect linearly (Figure 2).
The levels of Akt1, mTOR, p70S6K, eEF2, and PKCα
were higher at 12 h in all three samples of cells express-
ing CyPrPEGFP than in those of cells expressing EGFP
(Figure 7). At 24 h, in contrast, the levels of all proteins
analyzed were consistently lower than (or at the most,
equal to) those in cells expressing EGFP. Little changeFigure 6 Levels of CyPrPEGFP and EGFP in the samples used for
targeted secondary and tertiary analyses. Western blots of lysates
from three biological repeats expressing CyPrPEGFP (A) or EGFP (B)
for 12, 24, and 48 h. CyPrPEGFP (48 kDa) was detected by α-PrP and
α-GFP primary antibodies, and EGFP (28 kDa) by α-GFP antibody
only. Different exposures are shown for (A) and (B).
Figure 7 Lower levels of mTOR signaling proteins in cells expressing CyPrPEGFP for 24 and 48 h. Targeted secondary analyses of mTOR
signaling in N2a cells expressing CyPrPEGFP for 12, 24, or 48 h. The normalized expression levels of 10 protein kinases or substrates in each of the
three biological repeats are shown by individual color bars. Each color-coded category encompasses 20% changes in the levels of expression,
greater than 3 times the 6% linear changes detected by the technique. Proteins indicated by dashed lines were not analyzed. The expression
levels of mTORC1 and mTORC2 represent the levels of mTOR.
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eIF4E, and eEF2, which were expressed to their highest
levels in the cells expressing the lowest levels of CyPrPEGFP.
We performed a time-course analysis of the proteins
in the Akt1/p70S6K branch of the mTOR signaling path-
way (Figure 8). Akt1, mTOR, p70S6K, and eEF2, in theFigure 8 The levels of proteins in the Akt1/p70S6K branch of the mTOR
normalized expression levels of Akt1, mTOR, p70S6K, S6, eIF4B, and eEF2 in N2Akt1/p70S6K branch, were expressed to higher levels in
cells expressing CyPrPEGFP than in cells expressing EGFP
at 12 h, and then to lower levels at 24 or 48 h (except for
Akt at 24 h). The levels of the other p70S6K substrates
tested, S6 and eIF4B, also decreased with time. In sum-
mary, the levels of the proteins involved in Akt1/p70S6Ksignaling pathway change coordinately. Time-course analyses of the
a cells expressing CyPrPEGFP for 12, 24, or 48 h. Mean ± SD; n = 3.
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expression.
Inhibition of Hsp70-regulated Akt/p70S6K/eIF4B signaling
in cells expressing CyPrPEGFP
To test whether Akt1/p70S6K signaling was dysregulated
in cells expressing CyPrPEGFP, we characterized the acti-
vation states of the ten proteins previously tested. We
optimized phosphorylation-specific antibodies for the
sites directly phosphorylated by the relevant upstream
protein kinases. Akt is activated by phosphorylation on
S473 by mTORC2 and on T308 by 3-phosphoinositide-
dependent protein kinase 1 (PDK1) [58,59]. The synthe-
sis of Hsp70, which activates mTORC2, is inhibited in
cells expressing CyPrP [43,46]. We focused on Hsp70-
regulated phosphorylation of Akt1. No available anti-
body was specific for the phosphorylation at the
activation-specific site S473 on Akt1 only. We used an
antibody that detects S473 phosphorylation on all Akt
isoforms (Akt1, 2, and 3). Although mTOR phosphoryl-
ation is not required for mTORC1 activation, active
mTORC1 typically contains S2448 phosphorylated
mTOR [60]. We included an antibody specific for this
phosphorylation (P-S2448). We also included anti-
bodies specific for the phosphorylation at activation-
specific sites (activating phosphorylation) on AMPKα
(P-T172), Mnk1 (P-T197/202), PKCα (P-S657), p70S6K
(P-T389), S6 (P-S235/236; P-S240/244), eIF4B (P-S422)
and eIF4E (P-S209), or the inhibition-specific site (inhibi-
tory phosphorylation) on eEF2 (P-T56) [61-67]. The phos-
phorylation level of Akt (P-S473) at 12 h could be tested
in only two of the three independent biological replicates
due to limiting sample.
Active mTORC2 activates Akt by phosphorylation on
S473, which then activates mTORC1 which, in turn, ac-
tivates p70S6K by phosphorylation on T389. Active
p70S6K activates eIF4B by phosphorylation on S422.
The levels of activated Akt (P-S473), p70S6K (P-T389),
and eIF4B (P-S422) were consistently lower in cells ex-
pressing CyPrPEGFP than in cells expressing EGFP at all
times (Figure 9). Phosphorylated mTOR (P-S2448) levels
were also lower, or equal, in cells expressing CyPrPEGFP
than in those expressing EGFP, except for one sample at
48 h. We performed nonlinear regression analyses (the
regressions are non-linear) to test whether the changing
phosphorylation levels of any proteins involved in the
mTOR signaling pathway were different in cells expressing
CyPrPEGFP or EGFP. The levels of activated Akt (P-S473),
p70S6K (P-T389), and eIF4B (P-S422) were different in
cells expressing CyPrPEGFP or EGFP (replicates test for
lack-of-fit; Akt [P-S473], P = 0.02; p70S6K [P-T389], P =
0.001; eIF4B [P-S422], P = 0.0002) (Figure 10). In conclu-
sion, Akt/p70S6K/eIF4B signaling is inhibited in cells ex-
pressing CyPrPEGFP.Discussion
Here we describe the development of kinomic analyses
aimed at identifying signaling pathways dysregulated
during chronic pathologies. We designed and optimized
multiplex Western blots to quantitate the expression of
137 protein kinases (including regulatory subunits) in a
single membrane, and using only 1.2 mg of sample.
These multiplex Western blots were reproducible, sensi-
tive and linear, detecting 6% incremental changes in pro-
tein level. We tested the multiplex Western blots in a
kinomic screen of an in vitro model of prion pathogenesis,
N2a neuroblastoma cells expressing cytoplasmic PrP mu-
tants. The mTOR signaling pathway was identified in the
primary screen. The levels of proteins involved in the Akt1/
p70S6K branch of the mTOR signaling pathway changed
synchronously and were phosphorylated or unphosphory-
lated to their inhibited states in CyPrPEGFP expressing cells.
Hsp70 overexpression inhibits CyPrP-mediated toxicity
and the synthesis of Hsp70 is inhibited in cells expressing
CyPrPEGFP [43-45]. The inhibition of Hsp70-regulated
Akt/p70S6K/eIF4B signaling in cells expressing CyPrPEGFP
is fully consistent with those previous data [43-45], sup-
porting the ability of the approach to detect kinomic
changes. Inhibition of Hsp70-activated Akt/p70S6K/eIF4B
signaling may also be important in CyPrP pathogenesis.
Depletion of eIF4B by RNA interference promotes cell
death [48]. Hsp70 overexpression protects against this cell
death in part by promoting the expression of the anti-
apoptotic protein B-cell CLL/lymphoma 2 (Bcl-2) [68,69].
Active eIF4B is also required for the translation of Bcl-2
(and other proteins translated from mRNAs with highly
structured 5’ untranslated regions). CyPrP may promote
cell death by inhibiting Bcl-2 synthesis through the Akt/
p70S6K/eIF4B pathway. Overexpression of Akt1, mTOR,
and p70S6K in cells expressing CyPrPEGFP for 12 h may
well be an ultimately fruitless early attempt to overcome
neurotoxic inhibition of Akt/p70S6K/eIF4B signaling.
Active eIF4B promotes translation initiation by stimu-
lating the helicase activity of eukaryotic initiation factor
4A (eIF4A) and promoting ribosome binding [70-73].
Global protein synthesis is inhibited in cells expressing
CyPrPEGFP [43]. Previous studies have indicated that
eukaryotic initiation factor 2 alpha (eIF2α) was inhibited
in cells expressing CyPrPEGFP in a protein kinase R
(PKR)-dependent manner [43]. The inhibition of eIF4B
also inhibits protein synthesis [48], suggesting that the
inhibition of Akt/p70S6K/eIF4B signaling may too con-
tribute to the inhibition of protein synthesis in cells ex-
pressing CyPrPEGFP.
The kinomics approach we describe here is dependent
on the primary screens to first identify signaling path-
ways of potential interest. The protein kinases for the
primary screens were selected based on their potential
roles in prion or other neurodegenerative diseases, or in
Figure 9 Lower levels of activating phosphorylation of Akt, p70S6K, and eIF4B in cells expressing CyPrPEGFP. Targeted tertiary analyses of
mTOR signaling in N2a cells expressing CyPrPEGFP for 12, 24, or 48 h. The normalized absolute phosphorylation levels of 10 protein kinases or
substrates in each of the three biological repeats are shown by the color bars. The phosphorylation sites evaluated are indicated above each
protein. Proteins indicated by dashed lines were not analyzed. Due to limited sample, the levels of p-Akt at 12 h were measured only in two of
the three biological repeats. The color bars for S6 indicate the normalized phosphorylation levels of S235/236 (top) and S240/244 (bottom).
Shott et al. Virology Journal 2014, 11:175 Page 11 of 18
http://www.virologyj.com/content/11/1/175pathologies associated with prion disease. However, the
screens are extensive, evaluating almost one-third of the
protein kinases in the mouse (or human) genome. Other
kinomic analyses [15] used peptide arrays to identify dif-
ferent signaling pathways induced by PrPC stimulation
with a PrP antibody (6H4) or a small peptide (PrP106-
126). These assays are limited by the availability of the
peptide arrays and the different activities of several ki-
nases on small peptide or protein substrates. Other pre-
vious studies have only analyzed a limited number of
protein kinases (c-Abl, Src, Fyn, Yes, Lck, Lyn, Syk, Akt,
mTOR, p70S6K, CaMK2α, CDK5, PYK2, PKA, PKC,
PKR, PERK, MEK1/2 and MAPKs), based mostly on
their hypothesized involvement in prion disease patho-
genesis [13,14,17-20,22,74-88]. Such analyses provide in-
formation about the selected signaling pathways only.High-throughput reverse-phase protein arrays [89] can
also be used to analyze changes in protein kinase levels.
This approach requires highly specific antibodies, how-
ever, limiting the number of protein kinases that can be
analyzed. The antibodies included in the experiments
described here are also specific. Nonetheless, multiplex
Western blots discriminate specific from non-specific
binding (by molecular weight), tolerating some level of
cross-reactivity. More proteins can therefore be analyzed
by the multiplex Western blot approach than by protein
arrays.
High-throughput gene arrays have identified hundreds
of genes expressed differentially during, and a number of
cellular processes affected by, prion diseases [90-102].
However, only 518 or 540 of the approximately 30,000
genes in the human or mouse genomes encode for
































Figure 10 Inhibition of the Akt/p70S6K/eIF4B signaling pathway in cells expressing CyPrPEGFP. Time-course analysis of the normalized
absolute levels of phosphorylated Akt (P-S473), mTOR (P-S2448), p70S6K (P-T389), and eIF4B (P-S422) in N2a cells expressing CyPrPEGFP for 12, 24,
or 48 h; individual data and mean (p-Akt, square; p-mTOR, circle; p-p70S6K, triangle; p-eIF4B, inverted triangle). Due to limited sample, the levels
of p-Akt at 12 h were only measured in two biological repeats. The levels of all others were evaluated in three independent biological repeats.
Differences in changes in phosphorylation levels in cells expressing CyPrPEGFP and EGFP was analyzed by replicates test for lack-of-fit. *, P < 0.05;
**, P < 0.01; ***, P < 0.001.
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data thus results in very few clusters with multiple pro-
tein kinases, making it difficult to identify any particular
signaling pathway. Moreover, protein kinases are exten-
sively regulated post-transcriptionally and therefore their
mRNA and protein levels often do not correspond [103].
Global analyses of changes in microRNA (miRNA) which
may post-transcriptionally regulate as many as 60% of hu-
man genes [104], have also been performed during prion
disease pathogenesis, and have identified potentially dys-
regulated signaling pathways [100,105,106]. However, the
biological roles of most miRNAs have yet to be character-
ized, which makes it difficult to interpret the effects medi-
ated by many of the identified miRNAs.
The kinomics approach described here of course has
limitations, too. First, the primary screens identify sig-
naling pathways of potential interest using hierarchical
clustering. The identification of potentially dysregulated
pathways requires multiple kinases in the pathway to be
included in the primary screen. The 137 protein kinases
selected for the screens are involved in most of the best
characterized signaling pathways. The approach is thus
unable to detect signaling pathways that are less well
characterized, or for which only one or very few kinases
are included in the primary screen. Protein kinases are
also extensively regulated post-translationally. Dysregula-
tion of signaling pathways during chronic conditions
often result in, or is the result of, changes in expressionlevels of involved proteins. We therefore screened for
expression levels in the primary analysis. Consequently,
these screens cannot detect pathways that are only af-
fected post-translationally (unless the posttranslational
regulation is at the level of degradation). The described
approach is also unable to differentiate signaling path-
ways dysregulated as a result of disease from those crit-
ical in the pathogenesis. Previous studies have screened
protein kinase inhibitors and identified STI571 (an in-
hibitor of c-Abl, c-Kit, and PDGFR kinases) as promoting
PrPSc degradation [20]. The signaling pathway identified
by the kinomics approach can be tested with siRNA,
knockouts, or specific inhibitors, to identify whether it is
involved in CyPrP pathogenesis, or dysregulated as a re-
sult of it.
Conclusions
We used N2a cells expressing cytoplasmic PrP mutants
to test the sensitivity and specificity of kinomics analyses
developed to detect the dysregulation of specific signal-
ing pathways. The assays identified a dysregulated sig-
naling pathway which is fully consistent with previous
data. We conclude that the kinomics analyses are sensi-
tive and specific enough to detect signaling pathways
dysregulated in a simple in vitro model of prion patho-
genesis. We have now used these analyses to test critical
signaling pathways dysregulated in brains of prion-
infected animals (see companion paper).
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Cloning, cell culture and transfections
Cloning of CyPrPEGFP, CyPrPEGFP124stop and CyPrPEGFP124-
230 in pCEP4β (Life Technologies Inc., Carlsbad, California,
USA) was previously described [56]. Mouse N2a neuro-
blastoma cells were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10%
fetal bovine serum (Wisent, St. Bruno, Quebec, Canada).
Transfections were carried out using Exgen (MBI
Fermentas, Burlington, Ontario, Canada) or GeneCellin
(BioCellChallenge, Toulon, France), according to the man-
ufacturer’s protocol. To evaluate transfection efficiency,
cells were harvested with trypsin and EDTA and centri-
fuged for 5 min at 500 × g. Following a wash with PBS,
cells were fixed with 4% paraformaldehyde in 4% sucrose
for 20 min at room temperature, washed with PBS and an-
alyzed on a cytometer for GFP expression.
Mouse 3T3 cells were propagated in DMEM (Life
Technologies Inc.) supplemented with 5% fetal bovine
serum (FBS; PAA Laboratories GmbH, Pasching, Austria),
50 U/mL penicillin and 50 U/mL streptomycin (Life Tech-
nologies Inc.), at 37°C in 5% CO2.
Cell lysis and brain homogenization
Mouse 3T3 and transfected N2a cells were cultured to
approximately 85% confluency on 8 × 10 cm tissue cul-
ture dishes. All subsequent procedures were performed on
ice or at 4°C using reagents pre-chilled to 4°C. Each dish
was washed twice with 2 mL of phosphate-buffered saline
(PBS; 150 mM NaCl, 1 mM KH2PO4, 3 mM Na2HPO4,
pH 7.4). Cells were collected by scraping into freshly
prepared lysis buffer (0.2 mL per dish) (20 mM MOPS
[pH 7.0)], 2 mM EGTA, 5 mM EDTA, 1% Nonidet
P-40, 0.001% phosphatase inhibitor cocktail [Pierce,
Rockford, Illinois, USA], 0.002% protease inhibitor
cocktail [Sigma-Aldrich, St. Louis, Missouri, USA], 1
mM DTT, pH 7.2). The lysates were passed twice
through a 20 gauge needle, sonicated five times for 20 s
intervals at 88 W output (XL-2020; Misonix, Farming-
dale, New York, USA), and pre-cleared at 14,000 × g for
30 min (JA.14 rotor, Avanti J-E centrifuge; Beckman/
Coulter, Brea, California, USA). Approximately 1 mL vol-
umes of supernatant were aliquoted, snap frozen in liquid
nitrogen, and immediately stored at −80°C (3T3 lysates)
or shipped on dry ice and then stored at −80°C (N2a
lysates).
Brain homogenates were prepared using snap-frozen
mouse brains stored at −80°C. Weighed brains were ho-
mogenized in 3 mL freshly prepared lysis buffer per 250 mg
of brain, using a tissue homogenizer (TH; OMNI Inter-
national, Kennesaw, Georgia, USA) with disposable tips
(hard tissue OMNI tip; OMNI International). Homogenates
were then sonicated, centrifuged, and stored as described
for cell lysates.Protein quantitation
Protein concentration was determined by Bradford’s
assay (Bio-Rad Laboratories, Hercules, California, USA).
Protein concentration and equal sample loading were
then verified by preliminary sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE). Brain ho-
mogenates or cell lysates were mixed with equal volumes
of 2X SDS loading buffer (125 mM Tris-Cl [pH 6.8], 20%
glycerol, 4% SDS, 0.005% bromophenol blue, 260 mM
DTT), denatured at 100°C for 10 min, and loaded onto
10- or 15-well 8% SDS-PAGE gels (Mini-PROTEAN;
Bio-Rad Laboratories) (running buffer; 190 mM gly-
cine, 24.8 mM Tris, 0.1% SDS, pH 8.3). Proteins were run
through the stacking gel at 50 V, and then resolved for
90 min at 100 V, always at room temperature. Proteins were
stained with Coomassie blue G-250 (Bio-Safe Coomassie;
Bio-Rad Laboratories) according to the manufacturer’s in-
structions. Signal from Coomassie-stained protein was de-
tected using an Odyssey infrared imaging system (LI-COR
Biosciences, Lincoln, Nebraska, USA) in the 700 nm chan-
nel and quantitated using Odyssey 3.0 software (LI-COR
Biosciences). Protein amounts were calculated relative to a
pre-quantitated standard brain homogenate.
Western blot
All procedures were performed at room temperature
and all washes used gentle rocking. Proteins were dena-
tured by incubating for 10 min at 100°C with an equal
volume of 2X, or one-fifth volume of 6X (375 mM Tris-
Cl [pH 6.8], 60% glycerol, 12% SDS, 0.015% bromophe-
nol blue, 780 mM DTT), SDS-PAGE loading buffer.
For Western blots of PrP and EGFP, lysates from N2a
cells transfected with empty vector (100 μg), or vector en-
coding EGFP (50 μg), CyPrPEGFP (200 μg), CyPrPEGFP124-
stop (100 μg), or CyPrPEGFP124-230 (100 μg) were loaded
onto 15-well 10% SDS-PAGE gels (Mini-PROTEAN;
Bio-Rad Laboratories). Proteins were resolved as described
for protein quantitation and the gels were then equilibrated
in transfer buffer (384 mM glycine, 49.6 mM Tris, 20%
methanol, 0.01% SDS) [107] for 30 min. Meanwhile, poly-
vinylidene fluoride (PVDF) membranes (Immuno-Blot, 0.2
μm; Bio-Rad Laboratories) were soaked in methanol for 2
min, and equilibrated in transfer buffer for 20 min. For
each membrane, four sheets of filter paper were equili-
brated in transfer buffer for 5 min. Transfer cassettes
were loaded into a transfer tank (TE22; Hoefer, Holliston,
Massachusetts, USA) filled with transfer buffer at 4°C. Pro-
teins were transferred for 23 h at 4°C; 1 h at 54 mA, 4 h at
189 mA, 8 h at 270 mA and finally 10 h at 378 mA. The
temperature was maintained at 4°C by heat exchange
(Isotemp 1016D; Thermo Fisher Scientific, Waltham,
Massachusetts, USA) and gentle stirring of the transfer
buffer. After transfer, membranes were dried, soaked in
methanol for 2 min and then washed twice for 10 min
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KCl, 25 mM Tris, pH 7.6). Membranes were blocked for 1
h in 10% blocking buffer (Sigma-Aldrich) then simultan-
eously probed for 18 h at 4°C with primary antibodies
specific for GFP (a kind gift from Dr. Luc Berthiaume,
University of Alberta) and PrP (clone 3F4; a kind gift from
Dr. Deborah McKenzie, University of Alberta) diluted to
1:10,000 and 1:2,500, respectively, in 10% blocking buffer
with 0.1% Tween-20. Afterward, membranes were washed
in TBS with 0.1% Tween-20 (TBST) once for 5 min
and thrice for 10 min each. Membranes were incu-
bated with donkey anti-mouse IRDye 680- and donkey
anti-rabbit IRDye 800-labeled secondary antibodies
(LI-COR Biosciences), diluted to 1:20,000 in 10% block-
ing buffer with 0.1% Tween-20 and 0.01% SDS for 1 h.
Membranes were washed thrice in TBST for 10 min each
and once in TBS for 5 min. Signal from pre-stained pro-
tein standards and IRDye 680-labeled secondary antibody
was detected at 700 nm, and from IRDye 800-labeled sec-
ondary antibody at 800 nm, using an Odyssey infrared im-
aging system. Signal was quantitated using Odyssey 3.0
software. To evaluate the amounts of protein transferred
to the membranes, the membranes were stained with
Coomassie blue R-250 (Bio-Rad Laboratories) for 10 min
and destained with 40% methanol in 10% glacial acetic
acid thrice for 10 min each, or until excess stain was re-
moved. Signal from Coomassie-stained protein was de-
tected at 700 nm using the Odyssey and quantitated using
Odyssey 3.0 software.
For multiplex Western blot spiking experiments, 85 μg
(for p39 and TrkB) or 200 μg (for PKCγ, CaMK4, CDK1,
CHK1, RSK2, CDK4, PDGFRβ, BTK and PKCθ) of total
protein was loaded per linear cm of four- or five-well 8%
SDS-PAGE gels. For primary multiplex Western blots of
N2a cells expressing cytoplasmic PrP mutants, 150 μg of
protein was loaded per linear cm of single-well 8% SDS-
PAGE gels; 8 or 10% gels, as appropriate for the target
MW, loaded with 150, 300, or 450 μg of protein per lin-
ear cm were used for targeted analyses. Similar signal in-
tensities were reached using 150 μg of N2a or 200 μg of
brain lysates (Additional file 4: Figure S3). Proteins were
resolved and transferred to PVDF membranes as de-
scribed for Western blots of EGFP or CyPrPEGFP. Mem-
branes were blocked for 1 h in 10% blocking buffer
(Sigma-Aldrich) for protein-specific antibodies, or in 3%
BSA (Rockland, Gilbertsville, Pennsylvania, USA) for
phosphorylation-specific antibodies. Membranes were
rinsed briefly with TBS and positioned within a 20-lane
multi-screen apparatus (Bio-Rad Laboratories, Hercules,
California, USA). Meanwhile, combinations of primary
antibodies were diluted in 2.6 mL (primary blots) or
3.9 mL (spiked, secondary and tertiary blots) of 10%
blocking buffer or 3% BSA with 0.1% Tween-20. Six
hundred microliters of antibody solutions were loaded ineach lane of the multi-screen apparatus and incubated
for 18 h at 4°C. Membranes were then briefly washed
once with TBST within the multi-screen apparatus, re-
moved from the apparatus and further washed in TBST,
once for 5 min and four times for 15 min each. Mem-
branes were incubated with secondary antibody diluted
to 1:20,000 in 10% blocking buffer or 3% BSA with 0.1%
Tween-20 and 0.01% SDS for 1 h. Mouse monoclonal
primary antibodies were detected with goat anti-mouse
Alexa Fluor (Molecular Probes, Eugene, Oregon, USA)
or IRDye (LI-COR Biosciences) 680-labeled secondary
antibody. Rabbit or goat polyclonal primary antibodies
were detected with goat anti-rabbit or donkey anti-goat
(LI-COR Biosciences or Rockland) IRDye 800-labeled
secondary antibodies, respectively. Signal from pre-
stained protein standards and Alexa Fluor or IRDye 680-
labeled secondary antibody was detected at 700 nm, and
from IRDye 800-labeled secondary antibody at 800 nm,
using the Odyssey system. Signal was quantitated using
Odyssey 3.0 software.
Membranes with protein from cells expressing cytoplas-
mic PrP mutants were always stripped (only once) in par-
allel with the membranes from the control cells, under
conditions that minimize protein loss [108]. Membranes
were washed with a mild stripping buffer (25 mM glycine,
1% SDS, pH 2.0) once for 5 min and twice for 15 min
each. Membranes were then washed with TBST once and
TBS once for 5 min each. If necessary, they were further
washed with mild stripping buffer for a maximum of six
times of 15 min each. If still necessary, membranes were
then incubated with harsh stripping buffer (50 mM Tris-Cl
[pH 7.0], 2% SDS, 50 mM DTT) [109] for 15 min at 65°C
with gentle rocking. Membranes were then washed with
TBST once for 5 min and TBS twice for 10 min each.
Stripped membranes were blocked and reprobed with an-
other set of primary antibodies as described. No mem-
brane was stripped more than once.
Hierarchical cluster analysis
The integrated intensity levels (pixel volume) of proteins
in cells expressing cytoplasmic PrP mutants were nor-
malized to levels in cells expressing empty vector, and
then log2 transformed to avoid bias by proteins with ex-
treme changes in expression. Hierarchical clustering was
performed with Gene Cluster 3.0 [110] using city-block
distance (similarity metric) and complete linkage (clus-
tering method). Java Treeview was used to present the
resulting clusters [111].
Time-course data normalization
To evaluate the changes in protein and phosphorylation
levels in cells actually expressing CyPrPEGFP, the raw levels
(in the population containing expressing and non-expressing
cells) were corrected for differences in transfection efficiency
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to the levels in cells transfected with the EGFP expression






Gi: pixel volume in lysates from cells expressing EGFP
in replicate “i”,
Pi: pixel volume in lysates from cells expressing
CyPrPEGFP in replicate “i”, and
TE: transfection efficiency.
The differences in the integrated intensity levels (pixel
volume) in the populations of cells transfected with the
vectors expressing CyPrPEGFP or EGFP from the same bio-
logical replicate were corrected by the fraction of cells ac-
tually expressing the recombinant proteins (transfection
efficiency, 47, 45 and 34% for replicates 1, 2 and 3, respect-
ively), which are the cells in which the expressed proteins
directly induce changes in signaling, and added to the basal
levels (those in the population of cells transfected with the
vector expressing EGFP). The corrected levels in cells ex-
pressing CyPrPEGFP were then normalized to the levels in
cells expressing EGFP in the same biological replicate.
Statistical analyses
All data was analyzed using Prism (Version 5.0f; GraphPad
Software Inc., La Jolla, California, USA). For nonlinear re-
gression analyses, curves of the normalized phosphoryl-
ation levels were compared to a straight line (y-intercept =
1; slope = 0), representing the levels in cells expressing
EGFP, using a replicates test for lack-of-fit.
Additional files
Additional file 1: Figure S1. The protein kinases selected for primary
multiplex Western blots represent all major groups of the human protein
kinases. The human kinome, the protein kinase complement of the
human genome, clustered by protein kinase domain homology
(modified from Manning et al., 2002 [50]) The 145 protein kinases initially
selected for analyses are outlined in red. ATM, which is a member of the
atypical group of protein kinases, does not cluster with any group, and is
therefore not presented.
Additional file 2: Table S1. Accession number and antibody source for
each of the 127 protein kinases and 10 regulatory subunits optimized for
analyses in primary multiplex Western blots. One hundred and twenty-two
protein kinases or regulatory subunits included in the multiplex Western
blots were detected in 200 μg of mouse brain homogenate per linear well
cm. The other 15 (indicated by the asterisks) were detected in multiplex
Western blots using an equivalent amount of cell lysate from cycling 3T3
mouse fibroblasts. The human accession number and source of the
antibody used for each protein are indicated.
Additional file 3: Figure S2. Western blot for cytoplasmic PrP mutants
in N2a cells. Protein from N2a cell lysates transfected with empty vector,
or vector encoding CyPrPEGFP (CyPrP), CyPrPEGFP124stop (124stop), or
CyPrPEGFP124-230 (124-230) was resolved, transferred to membranes and
probed with α-PrP (which recognizes an epitope in residues 109-112) and
α-GFP antibodies. Molecular weights in kDa are indicated to the right.The arrowheads to the left indicate the molecular weight of CyPrPEGFP
(48 kDa), CyPrPEGFP124stop (38 kDa), and CyPrPEGFP 124-230 (34 kDa). Asterisks
indicate specific bands. CyPrPEGFP and CyPrPEGFP124stop were detected
by α-PrP and α-GFP antibodies, CyPrPEGFP 124-230, which does not have
the epitope recognized by the α-PrP antibody, was recognized only by
the α-GFP antibody. A background band with a molecular weight close
to that of CyPrPEGFP cross-reacted with the α-GFP antibody. Membranes
were stained with Coomassie to analyze total protein. Dashed lines separate
different blots.
Additional file 4: Figure S3. Frequency distribution of signal intensity
in N2a and mouse brain lysates. Signal for each protein kinase detected
was quantitated after multiplex Western blots with 200 μg of mouse
brain or 150 μg of N2a cell lysate per linear centimeter of gel. The
number of protein kinases yielding signal intensities in each range is
plotted. The frequency distribution of the signal intensity in both lysates
is highly similar.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RHS designed, developed, and performed kinomic analyses, and critically
evaluated the results. CG and GT provided the constructs, performed the
transfections, evaluated the transfection efficiencies and prepared the lysates.
RHS and CA performed the experiments in Figure 3. LMS designed the
study, critically evaluated the results, and co-wrote the manuscript with RHS.
XR critically revised the manuscript. All authors have read and approved the
final version of the manuscript.
Acknowledgements
This work was supported by PrioNet Canada Grants to LMS and XR, an
Alberta Prion Research Institute grant to LMS, a Burroughs Wellcome Fund
Award to LMS, and a Canadian Institutes for Health Research grant to XR
(MOP-89881). LMS is a Burroughs Wellcome Fund Investigator in the
Pathogenesis of Infectious Disease. RHS was supported by NSERC, 75th
Anniversary Graduate Student Award (Faculty of Medicine and Dentistry,
University of Alberta) and Queen Elizabeth II Doctoral Scholarship
(Government of the Province of Alberta).
Author details
1Department of Biochemistry and Centre for Prions and Protein Folding
Diseases (CPPFD), University of Alberta, Edmonton, AB T6G 2E1, Canada. 2Li Ka
Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada.
3Department of Biochemistry, Faculty of Medicine, Université de Sherbrooke,
Sherbrooke, QC J1H 5 N4, Canada.
Received: 5 June 2014 Accepted: 26 September 2014
Published: 3 October 2014
References
1. Martin L, Latypova X, Wilson C, Magnaudeix A, Perrin M, Yardin C, Terro F:
Tau protein kinases: involvement in Alzheimer’s disease. Ageing Res Rev
2013, 12:289–309.
2. Wood-Kaczmar A, Gandhi S, Wood N: Understanding the molecular causes
of Parkinson’s disease. Trends Mol Med 2006, 12:521–528.
3. Kinase-Disease association. [http://www.cellsignal.com/common/content/
content.jsp?id=science-tables-kinase-disease]
4. Knight Z, Lin H, Shokat K: Targeting the cancer kinome through
polypharmacology. Nat Rev Cancer 2010, 10:130–137.
5. Cohen P, Alessi D: Kinase drug discovery–what’s next in the field? ACS
Chem Biol 2013, 8:96–104.
6. Clinical Trials of Protein Kinase Inhibitors. [http://clinicaltrials.gov/ct2/results?
term=protein+kinase+inhibitor&Search=Search]
7. Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2014. 2014 [http://
www.researchandmarkets.com/reports/1196697/protein_kinase_inhibitors_
in_oncology_drug]
8. Fabbro D, Cowan-Jacob S, Mobitz H, Martiny-Baron G: Targeting cancer
with small-molecular-weight kinase inhibitors. Methods Mol Biol 2012,
795:1–34.
Shott et al. Virology Journal 2014, 11:175 Page 16 of 18
http://www.virologyj.com/content/11/1/1759. Bamborough P: System-based drug discovery within the human kinome.
Expert Opin Drug Discov 2012, 7:1053–1070.
10. Colby D, Prusiner S: Prions. Cold Spring Harb Perspect Biol 2011, 3:a006833.
11. Prusiner S: Prions. Proc Natl Acad Sci U S A 1998, 95:13363–13383.
12. Baeten L, Powers B, Jewell J, Spraker T, Miller M: A natural case of chronic
wasting disease in a free-ranging moose (Alces alces shirasi). J Wildl Dis
2007, 43:309–314.
13. Schwarz A, Burwinkel M, Riemer C, Schultz J, Baier M: Unchanged scrapie
pathology in brain tissue of tyrosine kinase Fyn-deficient mice.
Neurodegener Dis 2004, 1:266–268.
14. Moreno J, Radford H, Peretti D, Steinert J, Verity N, Martin M, Halliday M,
Morgan J, Dinsdale D, Ortori C, Barrett DA, Tsaytler P, Bertolotti A, Willis AE,
Bushell M, Mallucci GR: Sustained translational repression by eIF2alpha-P
mediates prion neurodegeneration. Nature 2012, 485:507–511.
15. Arsenault R, Li Y, Potter A, Griebel P, Kusalik A, Napper S: Induction of
ligand-specific PrP (C) signaling in human neuronal cells. Prion 2012,
6:477–488.
16. Yun S, Ertmer A, Flechsig E, Gilch S, Riederer P, Gerlach M, Schatzl H, Klein M:
The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion
by inhibiting prion propagation in the periphery. J Neurovirol 2007,
13:328–337.
17. Nordstrom E, Fisone G, Kristensson K: Opposing effects of ERK and
p38-JNK MAP kinase pathways on formation of prions in GT1-1 cells.
FASEB J 2009, 23:613–622.
18. Aguib Y, Heiseke A, Gilch S, Riemer C, Baier M, Schätzl H, Ertmer A:
Autophagy induction by trehalose counteracts cellular prion infection.
Autophagy 2009, 5:361–369.
19. Nordstrom E, Luhr K, Ibanez C, Kristensson K: Inhibitors of the mitogen-activated
protein kinase kinase 1/2 signaling pathway clear prion-infected cells from
PrPSc. J Neurosci 2005, 25:8451–8456.
20. Ertmer A, Gilch S, Yun S, Flechsig E, Klebl B, Stein-Gerlach M, Klein M,
Schatzl H: The tyrosine kinase inhibitor STI571 induces cellular clearance
of PrPSc in prion-infected cells. J Biol Chem 2004, 279:41918–41927.
21. Heiseke A, Aguib Y, Riemer C, Baier M, Schatzl H: Lithium induces
clearance of protease resistant prion protein in prion-infected cells by
induction of autophagy. J Neurochem 2009, 109:25–34.
22. Allard E, Grujic M, Fisone G, Kristensson K: Prion formation correlates with
activation of translation-regulating protein 4E-BP and neuronal
transcription factor Elk1. Neurobiol Dis 2013, 58:116–122.
23. Collinge J, Palmer M, Sidle K, Gowland I, Medori R, Ironside J, Lantos P:
Transmission of fatal familial insomnia to laboratory animals. Lancet 1995,
346:569–570.
24. Medori R, Montagna P, Tritschler H, LeBlanc A, Cortelli P, Tinuper P, Lugaresi
E, Gambetti P: Fatal familial insomnia: a second kindred with mutation of
prion protein gene at codon 178. Neurology 1992, 42:669–670.
25. Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y, Marino
S, Weissmann C, Aguzzi A: Normal host prion protein necessary for
scrapie-induced neurotoxicity. Nature 1996, 379:339–343.
26. Mallucci G, Dickinson A, Linehan J, Klohn P, Brandner S, Collinge J:
Depleting neuronal PrP in prion infection prevents disease and reverses
spongiosis. Science 2003, 302:871–874.
27. Stahl N, Borchelt D, Hsiao K, Prusiner S: Scrapie prion protein contains a
phosphatidylinositol glycolipid. Cell 1987, 51:229–240.
28. Baldwin M, Burlingame A, Prusiner S: Mass spectrometric analysis of a
GPI-anchored protein: the scrapie prion protein. Trends Anal Chem 1993,
12:239–248.
29. Drisaldi B, Stewart R, Adles C, Stewart L, Quaglio E, Biasini E, Fioriti L, Chiesa
R, Harris D: Mutant PrP is delayed in its exit from the endoplasmic
reticulum, but neither wild-type nor mutant PrP undergoes
retrotranslocation prior to proteasomal degradation. J Biol Chem 2003,
278:21732–21743.
30. Rane N, Yonkovich J, Hegde R: Protection from cytosolic prion protein
toxicity by modulation of protein translocation. EMBO J 2004, 23:4550–4559.
31. Levine C, Mitra D, Sharma A, Smith C, Hegde R: The efficiency of protein
compartmentalization into the secretory pathway. Mol Biol Cell 2005,
16:279–291.
32. Ma J, Lindquist S: Wild-type PrP and a mutant associated with prion
disease are subject to retrograde transport and proteasome
degradation. Proc Natl Acad Sci U S A 2001, 98:14955–14960.
33. Ma J, Lindquist S: Conversion of PrP to a self-perpetuating PrPSc-like
conformation in the cytosol. Science 2002, 298:1785–1788.34. Yedidia Y, Horonchik L, Tzaban S, Yanai A, Taraboulos A: Proteasomes and
ubiquitin are involved in the turnover of the wild-type prion protein.
EMBO J 2001, 20:5383–5391.
35. Lund C, Olsen C, Skogtvedt S, Tveit H, Prydz K, Tranulis M: Alternative
translation initiation generates cytoplasmic sheep prion protein. J Biol
Chem 2009, 284:19668–19678.
36. Rane N, Kang S, Chakrabarti O, Feigenbaum L, Hegde R: Reduced
translocation of nascent prion protein during ER stress contributes to
neurodegeneration. Dev Cell 2008, 15:359–370.
37. Bailly Y, Haeberle A, Blanquet-Grossard F, Chasserot-Golaz S, Grant N,
Schulze T, Bombarde G, Grassi J, Cesbron J, Lemaire-Vieille C: Prion protein
(PrPc) immunocytochemistry and expression of the green fluorescent
protein reporter gene under control of the bovine PrP gene promoter in
the mouse brain. J Comp Neurol 2004, 473:244–269.
38. Barmada S, Piccardo P, Yamaguchi K, Ghetti B, Harris D: GFP-tagged prion
protein is correctly localized and functionally active in the brains of
transgenic mice. Neurobiol Dis 2004, 16:527–537.
39. Mironov AJ, Latawiec D, Wille H, Bouzamondo-Bernstein E, Legname G,
Williamson R, Burton D, DeArmond S, Prusiner S, Peters P: Cytosolic prion
protein in neurons. J Neurosci 2003, 23:7183–7193.
40. Norstrom EM, Ciaccio MF, Rassbach B, Wollmann R, Mastrianni JA: Cytosolic
prion protein toxicity is independent of cellular prion protein expression
and prion propagation. J Virol 2007, 81:2831–2837.
41. Hegde R, Rane N: Prion protein trafficking and the development of
neurodegeneration. Trends Neurosci 2003, 26:337–339.
42. Ma J, Wollmann R, Lindquist S: Neurotoxicity and neurodegeneration
when PrP accumulates in the cytosol. Science 2002, 298:1781–1785.
43. Goggin K, Beaudoin S, Grenier C, Brown A, Roucou X: Prion protein
aggresomes are poly(A) + ribonucleoprotein complexes that induce a
PKR-mediated deficient cell stress response. Biochim Biophys Acta 2008,
1783:479–491.
44. Rambold A, Miesbauer M, Rapaport D, Bartke T, Baier M, Winklhofer K,
Tatzelt J: Association of Bcl-2 with misfolded prion protein is linked to
the toxic potential of cytosolic PrP. Mol Biol Cell 2006, 17:3356–3368.
45. Zhang J, Wang K, Guo Y, Shi Q, Tian C, Chen C, Gao C, Zhang B, Dong X:
Heat shock protein 70 selectively mediates the degradation of cytosolic
PrPs and restores the cytosolic PrP-induced cytotoxicity via a molecular
interaction. Virol J 2012, 9:303.
46. Martin J, Masri J, Bernath A, Nishimura R, Gera J: Hsp70 associates with
Rictor and is required for mTORC2 formation and activity. Biochem
Biophys Res Commun 2008, 372:578–583.
47. Rosner M, Fuchs C, Siegel N, Valli A, Hengstschlager M: Functional
interaction of mammalian target of rapamycin complexes in regulating
mammalian cell size and cell cycle. Hum Mol Genet 2009, 18:3298–3310.
48. Shahbazian D, Parsyan A, Petroulakis E, Topisirovic I, Martineau Y, Gibbs B,
Svitkin Y, Sonenberg N: Control of cell survival and proliferation
by mammalian eukaryotic initiation factor 4B. Mol Cell Biol 2010,
30:1478–1485.
49. Caenepeel S, Charydczak G, Sudarsanam S, Hunter T, Manning G: The
mouse kinome: discovery and comparative genomics of all mouse
protein kinases. Proc Natl Acad Sci U S A 2004, 101:11707–11712.
50. Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S: The protein
kinase complement of the human genome. Science 2002, 298:1912–1934.
51. Valin A, Cook J, Ross S, Saklad C, Gill G: Sp1 and Sp3 regulate transcription
of the cyclin-dependent kinase 5 regulatory subunit 2 (p39) promoter in
neuronal cells. Biochim Biophys Acta 2009, 1789:204–211.
52. Soppet D, Escandon E, Maragos J, Middlemas D, Reid S, Blair J, Burton L,
Stanton B, Kaplan D, Hunter T, Nikolics K, Parada LF: The neurotrophic
factors brain-derived neurotrophic factor and neurotrophin-3 are ligands
for the trkB tyrosine kinase receptor. Cell 1991, 65:895–903.
53. Klein R, Nanduri V, Jing S, Lamballe F, Tapley P, Bryant S, Cordon-Cardo C,
Jones K, Reichardt L, Barbacid M: The trkB tyrosine protein kinase is a
receptor for brain-derived neurotrophic factor and neurotrophin-3.
Cell 1991, 66:395–403.
54. Alevizopoulos A, Dusserre Y, Ruegg U, Mermod N: Regulation of the
transforming growth factor beta-responsive transcription factor CTF-1 by
calcineurin and calcium/calmodulin-dependent protein kinase IV. J Biol
Chem 1997, 272:23597–23605.
55. Cuadrado A, Molloy C, Pech M: Expression of protein kinase CI in NIH 3T3
cells increases its growth response to specific activators. FEBS Lett 1990,
260:281–284.
Shott et al. Virology Journal 2014, 11:175 Page 17 of 18
http://www.virologyj.com/content/11/1/17556. Grenier C, Bissonnette C, Volkov L, Roucou X: Molecular morphology and
toxicity of cytoplasmic prion protein aggregates in neuronal and
non-neuronal cells. J Neurochem 2006, 97:1456–1466.
57. Foster K, Fingar D: Mammalian target of rapamycin (mTOR): conducting
the cellular signaling symphony. J Biol Chem 2010, 285:14071–14077.
58. Sarbassov D, Guertin D, Ali S, Sabatini D: Phosphorylation and regulation
of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098–1101.
59. Alessi D, James S, Downes C, Holmes A, Gaffney P, Reese C, Cohen P:
Characterization of a 3-phosphoinositide-dependent protein kinase
which phosphorylates and activates protein kinase Balpha. Curr Biol 1997,
7:261–269.
60. Copp J, Manning G, Hunter T: TORC-specific phosphorylation of
mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker
for intact mTOR signaling complex 2. Cancer Res 2009, 69:1821–1827.
61. Hawley S, Davison M, Woods A, Davies S, Beri R, Carling D, Hardie D:
Characterization of the AMP-activated protein kinase kinase from rat
liver and identification of threonine 172 as the major site at which it
phosphorylates AMP-activated protein kinase. J Biol Chem 1996,
271:27879–27887.
62. Sarbassov D, Ali S, Kim D, Guertin D, Latek R, Erdjument-Bromage H, Tempst
P, Sabatini D: Rictor, a novel binding partner of mTOR, defines a
rapamycin-insensitive and raptor-independent pathway that regulates
the cytoskeleton. Curr Biol 2004, 14:1296–1302.
63. Burnett P, Barrow R, Cohen N, Snyder S, Sabatini D: RAFT1 phosphorylation
of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad
Sci U S A 1998, 95:1432–1437.
64. Ferrari S, Bandi H, Hofsteenge J, Bussian B, Thomas G: Mitogen-activated
70 K S6 kinase. Identification of in vitro 40 S ribosomal S6
phosphorylation sites. J Biol Chem 1991, 266:22770–22775.
65. Raught B, Peiretti F, Gingras A, Livingstone M, Shahbazian D, Mayeur G,
Polakiewicz R, Sonenberg N, Hershey J: Phosphorylation of eucaryotic
translation initiation factor 4B Ser422 is modulated by S6 kinases.
EMBO J 2004, 23:1761–1769.
66. Waskiewicz A, Johnson J, Penn B, Mahalingam M, Kimball S, Cooper J:
Phosphorylation of the cap-binding protein eukaryotic translation
initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol 1999,
19:1871–1880.
67. Redpath N, Price N, Severinov K, Proud C: Regulation of elongation factor-2
by multisite phosphorylation. Eur J Biochem 1993, 213:689–699.
68. Kelly S, Zhang Z, Zhao H, Xu L, Giffard R, Sapolsky R, Yenari M, Steinberg G:
Gene transfer of HSP72 protects cornu ammonis 1 region of the
hippocampus neurons from global ischemia: influence of Bcl-2.
Ann Neurol 2002, 52:160–167.
69. Jiang B, Liang P, Deng G, Tu Z, Liu M, Xiao X: Increased stability of Bcl-2 in
HSP70-mediated protection against apoptosis induced by oxidative
stress. Cell Stress Chaperones 2011, 16:143–152.
70. Rozen F, Edery I, Meerovitch K, Dever T, Merrick W, Sonenberg N:
Bidirectional RNA helicase activity of eucaryotic translation initiation
factors 4A and 4F. Mol Cell Biol 1990, 10:1134–1144.
71. Rozovsky N, Butterworth A, Moore M: Interactions between eIF4AI and its
accessory factors eIF4B and eIF4H. RNA 2008, 14:2136–2148.
72. Methot N, Pickett G, Keene J, Sonenberg N: In vitro RNA selection
identifies RNA ligands that specifically bind to eukaryotic translation
initiation factor 4B: the role of the RNA remotif. RNA 1996, 2:38–50.
73. Methot N, Song M, Sonenberg N: A region rich in aspartic acid, arginine,
tyrosine, and glycine (DRYG) mediates eukaryotic initiation factor 4B
(eIF4B) self-association and interaction with eIF3. Mol Cell Biol 1996,
16:5328–5334.
74. Combs C, Johnson D, Cannady S, Lehman T, Landreth G: Identification of
microglial signal transduction pathways mediating a neurotoxic
response to amyloidogenic fragments of beta-amyloid and prion
proteins. J Neurosci 1999, 19:928–939.
75. Jin J, Choi J, Lee H, Kim Y, Carp R, Choi E: Increased expression of CaM
kinase II alpha in the brains of scrapie-infected mice. Neurosci Lett 1999,
273:37–40.
76. Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche J, Lehmann S,
Launay J, Kellermann O: Signal transduction through prion protein.
Science 2000, 289:1925–1928.
77. Chiarini L, Freitas A, Zanata S, Brentani R, Martins V, Linden R: Cellular prion
protein transduces neuroprotective signals. EMBO J 2002,
21:3317–3326.78. Lopes J, Oliveira C, Agostinho P: Role of cyclin-dependent kinase 5 in the
neurodegenerative process triggered by amyloid-Beta and prion
peptides: implications for Alzheimer’s disease and prion-related
encephalopathies. Cell Mol Neurobiol 2007, 27:943–957.
79. Lopes M, Hajj G, Muras A, Mancini G, Castro R, Ribeiro K, Brentani R, Linden
R, Martins V: Interaction of cellular prion and stress-inducible protein 1
promotes neuritogenesis and neuroprotection by distinct signaling
pathways. J Neurosci 2005, 25:11330–11339.
80. Kanaani J, Prusiner S, Diacovo J, Baekkeskov S, Legname G: Recombinant
prion protein induces rapid polarization and development of synapses
in embryonic rat hippocampal neurons in vitro. J Neurochem 2005,
95:1373–1386.
81. Weise J, Sandau R, Schwarting S, Crome O, Wrede A, Schulz-Schaeffer W,
Zerr I, Bahr M: Deletion of cellular prion protein results in reduced Akt
activation, enhanced postischemic caspase-3 activation, and exacerbation
of ischemic brain injury. Stroke 2006, 37:1296–1300.
82. Krebs B, Dorner-Ciossek C, Schmalzbauer R, Vassallo N, Herms J, Kretzschmar H:
Prion protein induced signaling cascades in monocytes. Biochem Biophys
Res Commun 2006, 340:13–22.
83. Schneider B, Mutel V, Pietri M, Ermonval M, Mouillet-Richard S, Kellermann
O: NADPH oxidase and extracellular regulated kinases 1/2 are targets of
prion protein signaling in neuronal and nonneuronal cells. Proc Natl Acad
Sci U S A 2003, 100:13326–13331.
84. Monnet C, Gavard J, Mege R, Sobel A: Clustering of cellular prion protein
induces ERK1/2 and stathmin phosphorylation in GT1-7 neuronal cells.
FEBS Lett 2004, 576:114–118.
85. Lee H, Jun Y, Choi J, Kim J, Carp R, Kim Y: Activation of mitogen-activated
protein kinases in hamster brains infected with 263 K scrapie agent.
J Neurochem 2005, 95:584–593.
86. Nixon R: Prion-associated increases in Src-family kinases. J Biol Chem
2005, 280:2455–2462.
87. Caetano F, Lopes M, Hajj G, Machado C, Pinto Arantes C, Magalhaes A,
Vieira Mde P, Americo T, Massensini A, Priola S, Vorberg I, Gomez MV,
Linden R, Prado VF, Martins VR, Prado MA: Endocytosis of prion
protein is required for ERK1/2 signaling induced by stress-inducible
protein 1. J Neurosci 2008, 28:6691–6702.
88. Roffe M, Beraldo F, Bester R, Nunziante M, Bach C, Mancini G, Gilch S,
Vorberg I, Castilho B, Martins V, Hajj G: Prion protein interaction with
stress-inducible protein 1 enhances neuronal protein synthesis via
mTOR. Proc Natl Acad Sci U S A 2010, 107:13147–13152.
89. Spurrier B, Ramalingam S, Nishizuka S: Reverse-phase protein lysate
microarrays for cell signaling analysis. Nat Protoc 2008,
3:1796–1808.
90. Booth S, Bowman C, Baumgartner R, Dolenko B, Sorensen G, Robertson C,
Coulthart M, Phillipson C, Somorjai R: Molecular classification of scrapie
strains in mice using gene expression profiling. Biochem Biophys Res
Commun 2004, 325:1339–1345.
91. Booth S, Bowman C, Baumgartner R, Sorensen G, Robertson C, Coulthart M,
Phillipson C, Somorjai R: Identification of central nervous system genes
involved in the host response to the scrapie agent during preclinical
and clinical infection. J Gen Virol 2004, 85:3459–3471.
92. Brown A, Rebus S, McKimmie C, Robertson K, Williams A, Fazakerley J: Gene
expression profiling of the preclinical scrapie-infected hippocampus.
Biochem Biophys Res Commun 2005, 334:86–95.
93. Riemer C, Neidhold S, Burwinkel M, Schwarz A, Schultz J, Kratzschmar J,
Monning U, Baier M: Gene expression profiling of scrapie-infected brain
tissue. Biochem Biophys Res Commun 2004, 323:556–564.
94. Sawiris G, Becker K, Elliott E, Moulden R, Rohwer R: Molecular analysis of
bovine spongiform encephalopathy infection by cDNA arrays. J Gen Virol
2007, 88:1356–1362.
95. Skinner P, Abbassi H, Chesebro B, Race R, Reilly C, Haase A: Gene
expression alterations in brains of mice infected with three strains of
scrapie. BMC Genomics 2006, 7:114.
96. Xiang W, Windl O, Wunsch G, Dugas M, Kohlmann A, Dierkes N, Westner I,
Kretzschmar H: Identification of differentially expressed genes in
scrapie-infected mouse brains by using global gene expression
technology. J Virol 2004, 78:11051–11060.
97. Xiang W, Hummel M, Mitteregger G, Pace C, Windl O, Mansmann U,
Kretzschmar H: Transcriptome analysis reveals altered cholesterol
metabolism during the neurodegeneration in mouse scrapie model.
J Neurochem 2007, 102:834–847.
Shott et al. Virology Journal 2014, 11:175 Page 18 of 18
http://www.virologyj.com/content/11/1/17598. Sorensen G, Medina S, Parchaliuk D, Phillipson C, Robertson C, Booth S:
Comprehensive transcriptional profiling of prion infection in mouse
models reveals networks of responsive genes. BMC Genomics 2008, 9:114.
99. Filali H, Martin-Burriel I, Harders F, Varona L, Lyahyai J, Zaragoza P, Pumarola
M, Badiola J, Bossers A, Bolea R: Gene expression profiling and association
with prion-related lesions in the medulla oblongata of symptomatic
natural scrapie animals. PLoS One 2011, 6:e19909.
100. Majer A, Medina S, Niu Y, Abrenica B, Manguiat K, Frost K, Philipson C,
Sorensen D, Booth S: Early mechanisms of pathobiology are revealed by
transcriptional temporal dynamics in hippocampal CA1 neurons of prion
infected mice. PLoS Pathog 2012, 8:e1003002.
101. Hwang D, Lee I, Yoo H, Gehlenborg N, Cho J, Petritis B, Baxter D, Pitstick R,
Young R, Spicer D, Price ND, Hohmann JG, Dearmond SJ, Carlson GA, Hood
LE: A systems approach to prion disease. Mol Syst Biol 2009, 5:252.
102. Kim H, Snyder G, Blazey T, Race R, Chesebro B, Skinner P: Prion disease
induced alterations in gene expression in spleen and brain prior to
clinical symptoms. Adv Appl Bioinform Chem 2008, 1:29–50.
103. Gygi S, Rochon Y, Franza B, Aebersold R: Correlation between protein and
mRNA abundance in yeast. Mol Cell Biol 1999, 19:1720–1730.
104. Friedman R, Farh K, Burge C, Bartel D: Most mammalian mRNAs are
conserved targets of microRNAs. Genome Res 2009, 19:92–105.
105. Saba R, Goodman C, Huzarewich R, Robertson C, Booth S: A miRNA
signature of prion induced neurodegeneration. PLoS One 2008, 3:e3652.
106. Montag J, Hitt R, Opitz L, Schulz-Schaeffer W, Hunsmann G, Motzkus D:
Upregulation of miRNA hsa-miR-342-3p in experimental and idiopathic
prion disease. Mol Neurodegener 2009, 4:36.
107. Otter T, King S, Witman G: A two-step procedure for efficient electrotransfer
of both high-molecular-weight (greater than 400,000) and low-molecular-
weight (less than 20,000) proteins. Anal Biochem 1987, 162:370–377.
108. Yeung Y, Stanley E: A solution for stripping antibodies from polyvinylidene
fluoride immunoblots for multiple reprobing. Anal Biochem 2009, 389:89–91.
109. Harlow E, Lane D: Using Antibodies: A Laboratory Manual. New York: Cold
Spring Harbor Laboratory Press; 1999.
110. de Hoon M, Imoto S, Nolan J, Miyano S: Open source clustering software.
Bioinformatics 2004, 20:1453–1454.
111. Saldanha A: Java Treeview–extensible visualization of microarray data.
Bioinformatics 2004, 20:3246–3248.
doi:10.1186/1743-422X-11-175
Cite this article as: Shott et al.: Development of kinomic analyses to
identify dysregulated signaling pathways in cells expressing cytoplasmic
PrP. Virology Journal 2014 11:175.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
